Mogamulizumab (NCT04256018)

Name: Mogamulizumab trial for Sezary Syndrome (NCT04256018)
Uploaded: 2026-10-31T22:34:43.038Z
Duration: 1 min 13 s
Description: Mogamulizumab trial for Sezary Syndrome (NCT04256018). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04256018.

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome: a one-minute explainerNCT042560181 min

Mogamulizumab trial for Sezary Syndrome (NCT04256018). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage IB–IV mycosis fungoides or Sézary syndrome after at least one standard treatment. Stage IA and central-nervous-system disease are excluded.

The idea: mogamulizumab targets CCR4 and can recruit immune attack. Researchers combine its infusions with low-dose radiation to the entire skin: twelve gray over two to three weeks. Infusions start weekly, then change to every two weeks after the first month. Researchers assess response, safety, and tolerability.

This phase 2 study plans 30 patients. Youn Kim leads at Stanford Cancer Center, Stanford, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.